List of Excipients in Branded Drug DACTINOMYCIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Prasco Laboratories	DACTINOMYCIN	dactinomycin	66993-489	MANNITOL

Generic Drugs Containing DACTINOMYCIN

Company	Ingredient	NDC	Excipient
XGen Pharmaceuticals DJB Inc	dactinomycin	39822-2100	MANNITOL
Hisun Pharmaceuticals USA Inc	dactinomycin	42658-008	MANNITOL
Eugia US LLC	dactinomycin	55150-431	MANNITOL
Eugia US LLC	dactinomycin	55150-928	MANNITOL
Mylan Institutional LLC	dactinomycin	67457-513	MANNITOL
Mylan Institutional LLC	dactinomycin	67457-928	MANNITOL

What are the Most Frequently-Used Excipients in DACTINOMYCIN?

# Of NDCs	Excipient
7	MANNITOL
1	WATER

Dactinomycin Excipient Strategy and Commercial Opportunities

Last updated: August 3, 2026

Dactinomycin is a legacy cytotoxic antibiotic used primarily for Wilms tumor, rhabdomyosarcoma, trophoblastic neoplasia, and selected pediatric oncology indications. Its commercial opportunity is concentrated in sterile injectable supply, formulation resilience, hospital procurement, and differentiated ready-to-use presentations rather than new oral or chronic-delivery products. The core excipient strategy is conservative: preserve chemical potency, minimize extractables and particulate risk, protect healthcare workers, and maintain reliable reconstitution of a highly potent cytotoxic drug.

What is the current dactinomycin formulation?

The established product is a sterile, preservative-free lyophilized powder for intravenous administration. The U.S. reference product, Cosmegen, contains 0.5 mg of dactinomycin per vial with mannitol as the principal excipient. The product is reconstituted with sterile water before administration.[1]

Attribute	Dactinomycin product profile
Active ingredient	Dactinomycin
Therapeutic class	Cytotoxic antineoplastic antibiotic
Typical dosage form	Sterile lyophilized powder
Route	Intravenous
Common vial strength	0.5 mg
Principal excipient	Mannitol
Preservative	None in the reference presentation
Key formulation risks	Potency loss, light sensitivity, aggregation, adsorption, particulates
Handling classification	Hazardous cytotoxic drug
Primary buyers	Hospitals, oncology centers, specialty distributors, group purchasing organizations

Dactinomycin is a potent DNA-binding agent. Its formulation must support low-dose accuracy, controlled reconstitution, chemical stability, and safe handling. A formulation that adds excipients without a clear stability or administration benefit could increase regulatory and manufacturing risk without improving clinical value.

What excipients are used in dactinomycin injection?

Mannitol is the principal disclosed excipient in the established U.S. lyophilized formulation. It provides bulking during freeze-drying and helps create a physically acceptable cake for reconstitution. The formulation does not rely on a complex buffer system, surfactant package, preservative, or multi-excipient delivery platform.[1]

Why mannitol is commercially useful

Mannitol is suitable for sterile lyophilized products because it:

• Provides solid mass for low-dose drug products.
• Supports formation of a visually acceptable lyophilized cake.
• Has extensive parenteral-use precedent.
• Avoids the antimicrobial-preservative burden associated with multidose products.
• Can be sourced from established pharmaceutical excipient suppliers.

Mannitol can crystallize during freezing or storage. Its physical form, concentration, thermal history, and interaction with dactinomycin must therefore be controlled. A formulation developer should not assume that replacing or increasing mannitol will improve stability. The resulting cake structure, reconstitution time, residual moisture, and potency profile require direct development studies.

Candidate excipient classes

Potential excipient options include:

Excipient class	Potential role	Principal concern
Mannitol	Bulking agent and cake former	Crystallization and phase behavior
Sucrose	Amorphous stabilizer and bulking support	Hygroscopicity and cake collapse
Trehalose	Lyoprotectant and amorphous stabilizer	Higher cost and moisture sensitivity
Glycine	Bulking and cake-structure modifier	pH and crystallization effects
Polysorbate 20 or 80	Surface protection	Oxidation, peroxide formation, particles
Histidine or phosphate buffer	pH control	Compatibility, ionic strength, precipitation
Sodium chloride	Tonicity adjustment	Limited value in a reconstituted concentrate
Amino acids	Stabilization or cake modification	Added regulatory and analytical complexity

For dactinomycin, the commercial presumption should be that the lowest-excipient formulation is preferable unless testing demonstrates a material improvement in stability or administration. Surfactants deserve particular scrutiny because oxidized surfactant impurities and subvisible particles can create injectable-product risks.

What formulation patents could protect dactinomycin products?

The strongest potential intellectual-property opportunities are likely to involve a specific formulation or presentation rather than dactinomycin itself. Dactinomycin is an old active ingredient, and composition-of-matter exclusivity is no longer commercially relevant for the established molecule.

Potentially protectable concepts include:

1. A stable liquid dactinomycin formulation.
2. A defined lyophilized composition with a specific excipient ratio.
3. A ready-to-use or ready-to-administer presentation.
4. A low-particulate formulation with defined container-closure materials.
5. A reconstitution system that reduces operator exposure.
6. A formulation with extended refrigerated or room-temperature stability.
7. A dual-chamber vial or closed-system transfer device.
8. A manufacturing process that improves potency recovery or reduces degradation products.

A patent must contain a credible technical distinction. Broad claims covering dactinomycin plus ordinary parenteral excipients could face substantial obviousness and written-description challenges. The most defensible claims would tie the composition to measured outcomes, such as a defined degradation threshold, reconstitution time, particulate limit, or stability period.

Patent strength by product concept

Product concept	Likely patent strength	Commercial value
Dactinomycin plus mannitol in a conventional vial	Low	Low to moderate
New lyophilized excipient ratio with demonstrated stability	Moderate	Moderate
Stable liquid concentrate	Moderate to high if technically difficult	High
Ready-to-use diluted infusion product	Moderate	High if shelf life is practical
Closed-system reconstitution kit	Moderate	Moderate to high
Novel container-closure and light-protection system	Moderate	Moderate
New therapeutic use	Limited unless clinically differentiated	Variable

A freedom-to-operate review should cover U.S., European, Japanese, and other major oncology markets. The relevant search should include dactinomycin, actinomycin D, lyophilized cytotoxic injectables, container-closure systems, closed-system transfer devices, and ready-to-use oncology formulations.

What excipient strategy best supports a dactinomycin generic?

A generic manufacturer has two principal routes: replicate the established lyophilized formulation or develop a differentiated presentation. The first route has lower development risk. The second may create commercial separation but requires stronger stability, compatibility, and regulatory evidence.

Strategy 1: Reference-like lyophilized powder

This approach uses mannitol or a closely related bulking system and preserves the established vial configuration. Its advantages are:

• Familiar hospital handling.
• Lower formulation complexity.
• Established reconstitution workflow.
• Reduced clinical and regulatory differentiation burden.
• Easier compatibility with existing pharmacy procedures.

The main commercial disadvantage is substitutability. A reference-like product will often compete primarily on supply reliability, price, contract access, and shortage performance.

Strategy 2: Enhanced lyophilized formulation

An improved lyophilized product could use a stabilizing sugar or optimized bulking system to increase resistance to temperature excursions and reduce reconstitution variability. The product would need evidence showing that the improvement is meaningful under realistic distribution conditions.

Useful development endpoints include:

• Assay retention after accelerated storage.
• Degradation-product formation.
• Reconstitution time.
• Visible and subvisible particulate levels.
• Cake appearance and shrinkage.
• Container-closure integrity.
• Compatibility with infusion bags and administration sets.
• Stability after reconstitution.
• Light-exposure tolerance.

Strategy 3: Ready-to-use liquid product

A liquid dactinomycin formulation could remove pharmacy reconstitution steps and reduce manipulation of a hazardous drug. It would also face the highest technical risk. Dactinomycin concentration, pH, oxygen exposure, adsorption, light exposure, and container materials would all require optimization.

A commercially viable liquid product would need:

• A clinically useful shelf life.
• Robust room-temperature or refrigerated storage.
• Low particulate burden.
• Compatible primary packaging.
• Low adsorption to syringes, bags, and tubing.
• A validated light-protection system.
• A clear hazardous-drug handling procedure.

The opportunity is significant because ready-to-use oncology products can reduce preparation time and compounding errors. The barrier is that a liquid product may require a novel formulation, a new manufacturing process, and a more extensive stability package.

What commercial opportunities exist for dactinomycin formulations?

The main opportunity is operational improvement in hospital use. Dactinomycin is administered in small doses, often to pediatric or specialty oncology patients, where dosing accuracy and preparation reliability matter.

Ready-to-administer oncology product

A prefilled syringe, pharmacy-ready vial, or diluted infusion container could reduce preparation steps. A prefilled syringe would need careful evaluation because dactinomycin is a cytotoxic drug and the syringe material, stopper, lubricants, and needle system could affect stability and extractables.

Closed-system reconstitution

A vial integrated with a closed-system transfer device could reduce operator exposure and contain aerosols or droplets during reconstitution. The commercial value would depend on compatibility with hospital pharmacy equipment and whether the device adds meaningful cost.

Pediatric dose optimization

The 0.5-mg vial format can create residual drug and dosing inefficiency when patient doses are small. Commercial opportunities include:

• Lower-strength vials.
• Unit-dose presentations.
• Pharmacy-ready dose bands.
• Packaging that reduces vial overfill and waste.
• Stability data supporting dose preparation in advance.

Any smaller vial must be assessed against manufacturing loss, fill-finish cost, minimum batch size, and hospital purchasing behavior.

Supply reliability and shortage mitigation

For a legacy oncology injectable, consistent supply can be more valuable than a complex formulation. A manufacturer with multiple API sources, redundant sterile-finish capacity, and strong quality systems can compete effectively even without a major excipient innovation.

Operational differentiation may include:

• Dual-source API qualification.
• Domestic or regional fill-finish capacity.
• Longer dating.
• Improved temperature-excursion management.
• Better order allocation during shortages.
• Hospital-specific packaging and inventory programs.

What FDA regulatory status applies to dactinomycin?

Dactinomycin is an FDA-approved antineoplastic drug. The reference product is Cosmegen, supplied as a sterile lyophilized product for intravenous use. The product labeling includes boxed-warning-level cytotoxic handling concerns and emphasizes that dactinomycin must be administered by experienced oncology personnel.[1]

For a generic injectable, the regulatory pathway generally involves an abbreviated new drug application where the product meets applicable requirements for sameness, quality, strength, route, dosage form, and labeling. A formulation that materially changes the excipient system or creates a new liquid or ready-to-use presentation may require additional development and regulatory justification.

Critical CMC areas include:

• Sterility assurance.
• Endotoxin control.
• Potency and related substances.
• Reconstitution performance.
• Particulate matter.
• Container-closure integrity.
• Extractables and leachables.
• Photostability.
• In-use stability.
• Compatibility with administration materials.

What is the Orange Book and exclusivity status of dactinomycin?

Dactinomycin is a long-established small-molecule drug. Its original regulatory exclusivity and composition-of-matter patent terms have expired. Current commercial protection, if any, is more likely to arise from product-specific formulation, process, device, or regulatory rights than from the active ingredient.

The Orange Book should be reviewed for current reference-listed-drug information, patent listings, and exclusivity codes before a launch decision. A conventional generic dactinomycin injectable would generally face a mature market structure rather than a new-molecule exclusivity barrier.[2]

Paragraph IV challenge risk

A Paragraph IV certification could be relevant if an Orange Book-listed patent remains associated with a reference product. For a legacy dactinomycin product, the most likely risk areas would involve:

• A formulation patent.
• A delivery device.
• A manufacturing process with listed claims.
• A specific dosage form or presentation.

The commercial value of a Paragraph IV strategy would depend on the remaining patent term, the reference product’s market share, the availability of alternative manufacturers, and whether the proposed generic can avoid the listed claims. No assumption should be made that a legacy drug has no active listed patents without checking the current Orange Book entry.

Which companies could compete in dactinomycin?

Competition is likely to come from the reference-product sponsor, generic injectable manufacturers, specialty oncology suppliers, and contract manufacturers with cytotoxic fill-finish capability.

The relevant competitive factors are:

Competitive factor	Importance
FDA-approved product status	High
Reliable sterile supply	Very high
Cytotoxic manufacturing capability	Very high
API sourcing	High
Contract and group purchasing access	High
Vial pricing	High
Shortage performance	High
Ready-to-use presentation	Moderate to high
Patent differentiation	Moderate
Pediatric packaging	Moderate

The market is unlikely to reward a formulation change that raises acquisition cost without reducing pharmacy labor, preparation risk, waste, or shortage exposure.

What litigation and settlement issues affect dactinomycin?

Dactinomycin is not generally associated with the type of active patent-litigation cycle seen in newer oncology products. The principal legal risks for a new entrant would be ordinary ANDA litigation, product-specific patent assertions, manufacturing know-how disputes, and regulatory enforcement involving sterile manufacturing.

A settlement agreement could affect launch timing if a listed patent exists and the generic applicant resolves litigation with the reference sponsor. The business value of a settlement would depend on the agreed launch date, authorized-generic rights, supply terms, and restrictions on formulation or presentation.

How does dactinomycin compare with other cytotoxic injectables?

Dactinomycin has a narrower and more specialized commercial profile than widely used agents such as doxorubicin, vincristine, or cyclophosphamide.

Product characteristic	Dactinomycin	Broad-use cytotoxic injectable
Patient population	Narrower, often pediatric or rare oncology use	Larger
Annual volume	Lower	Often higher
Formulation complexity	Moderate	Variable
Shortage sensitivity	High because alternatives may be limited	High
Hospital preparation burden	Meaningful	Variable
Ready-to-use opportunity	High relative to volume	Depends on drug
Price competition	Strong in generic products	Strong
Supply reliability value	Very high	High
Patent opportunity	Mainly formulation or device	May include newer-use patents

Dactinomycin’s lower volume can make development difficult to justify, but its specialized clinical role can support premium pricing for reliable supply, reduced waste, and simplified preparation.

What generic launch scenarios exist for dactinomycin?

Conventional generic launch

A manufacturer launches a reference-like lyophilized vial and competes on price, availability, and contracts. This is the lowest-risk pathway but offers limited differentiation.

Shortage-driven launch

A supplier enters after a supply disruption or uses secondary manufacturing capacity to serve hospitals seeking an alternative source. Regulatory and quality readiness are critical because oncology hospitals may change suppliers quickly during shortages.

Formulation-differentiated launch

A company launches a more stable lyophilized product, ready-to-use liquid, or pharmacy-ready presentation. This requires stronger technical evidence but may support better pricing and hospital adoption.

Platform portfolio launch

A sterile cytotoxic manufacturer uses dactinomycin as one product in a broader oncology injectable portfolio. This can improve sales efficiency, distributor access, manufacturing utilization, and contracting leverage.

Key Takeaways

• The established dactinomycin formulation is a simple sterile lyophilized product using mannitol as the principal excipient.
• The highest-value excipient work concerns stability, reconstitution, particulate control, and container compatibility.
• A conventional generic is likely to compete mainly on supply reliability, price, and procurement access.
• The strongest commercial differentiation is a ready-to-use or pharmacy-ready presentation that reduces hazardous-drug manipulation.
• Liquid formulations offer higher commercial upside but also greater chemical, packaging, and regulatory risk.
• Dactinomycin’s original molecule and early patent protection are long expired; current legal risk should be assessed through the live Orange Book listing and any product-specific patents.
• Pediatric dosing, vial waste, closed-system reconstitution, and shortage resilience are the clearest commercial opportunity areas.
• Manufacturing capability for sterile cytotoxic products may be a stronger barrier than the excipient itself.

FAQs

Is dactinomycin a biologic or a small-molecule drug?

Dactinomycin is a small-molecule cytotoxic antibiotic. Biosimilar regulation does not apply. Competition proceeds through conventional drug-product and generic pathways rather than the biosimilar pathway.

Can dactinomycin be formulated as a preservative-containing multidose vial?

The established product is preservative-free and supplied as a single-dose sterile presentation. A multidose product would introduce antimicrobial effectiveness, sterility, compatibility, and cytotoxic-handling issues that would require separate development and regulatory support.

What is the most valuable new excipient for dactinomycin?

No single excipient is predictably superior. The highest-value strategy is an optimized system that demonstrably improves potency retention, reconstitution, or in-use stability without increasing particles, degradation products, or packaging risk.

Could a ready-to-use dactinomycin product command a premium price?

It could, if it reduces pharmacy labor, hazardous-drug exposure, preparation errors, or product waste. The premium would need to offset the cost of specialized liquid stability, packaging, validation, and distribution controls.

Is dactinomycin an attractive target for a new pharmaceutical manufacturer?

It is most attractive to a manufacturer with existing cytotoxic sterile-fill capacity, hospital oncology distribution, and a broader injectable portfolio. A standalone product investment is less compelling unless the company has a differentiated presentation or a credible supply-reliability advantage.

References

1. Merck Sharp & Dohme LLC. (2023). Cosmegen (dactinomycin for injection) prescribing information. U.S. Food and Drug Administration and DailyMed.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

3. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. General chapters for sterile preparations, particulate matter, and pharmaceutical compounding.

4. National Institute for Occupational Safety and Health. (2023). NIOSH list of hazardous drugs in healthcare settings. Centers for Disease Control and Prevention.